Matinas BioPharma Investor Presentation Deck slide image

Matinas BioPharma Investor Presentation Deck

19 LNC Therapeutic Cargo Experience to Date Infection Inflammation Oncology In Vivo Animal Studies Animal model Cystic fibrosis mouse model BALB/c mouse flu model [Multiple mouse fungal models] Pneumocystis mouse model Mouse SARS-CoV-2 model Rat footpad inflammation model GvHD mouse model LPS mouse model Psoriasis (IMQ) mouse model* DSS colitis mouse model* Lymphocytic leukemia mouse model Syngeneic mouse melanoma model* Cargo Amikacin ASO Flu protein siRNA Amphotericin- B Atovaquone Remdesivir NSAID ST1959 RNAi RNAi RNAi ASO Docetaxel COPYRIGHT MATINAS BIOPHARMA 2024 Indication Mucocutaneous candidiasis Job's syndrome, NIH Vulvovaginal Candidiasis (VVC) Phase 2 HIV/ cryptococcal meningitis, Phase 2 * new Human Clinical Trials * new * new Cargo Amphotericin - B Amphotericin - B Amphotericin - B MATINAS BIOPHARMA
View entire presentation